N. L. Berinstein

Articles by N. L. Berinstein

In Vivo Purging With Rituximab Prior to Stem Cell Collection Is Associated With Persistent Molecular Evidence of t(14;18) That Often Disappears Post-Transplant in Patients With Follicular Lymphoma

ByR. J. Buckstein,K. Imrie,D. Spaner,L. Bordeleau,T. Tompkins,E. Iakhnina,N. Pennell,A. Coovadia,M. Reis,K. Hewitt,P. Richardson,A. Lima,J. B. Robinson,M. Lim,B. Ordonez-Perez,N. L. Berinstein

March 1st 2000

We previously reported that “in vivo purging” with rituximab (Rituxan) during stem-cell collection is safe and does not adversely affect engraftment. We now report on our transplant experience with rituximab. From June 1998 to December

Latest Updated Articles

In Vivo Purging With Rituximab Prior to Stem Cell Collection Is Associated With Persistent Molecular Evidence of t(14;18) That Often Disappears Post-Transplant in Patients With Follicular Lymphoma
March 1st 2000

Trending on CancerNetwork

Melanoma Vaccine Receives FDA Fast Track Designation

NCCN Guidelines Recommend Taletrectinib for ROS1+ NSCLC Subtype

Targeting NAMPT and KRAS in Pancreatic Ductal Adenocarcinoma

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis